Payment overview · 2025
General Payments
$553.64
28 reported records · 7 companies
Healthcare provider profile · identity verified
Thomas Ries Yuellig, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CINCINNATI, OH · NPI 1609873827
Verified facts
What the public records show
CMS Open Payments records show Thomas Ries Yuellig, MD received $553.64 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 39.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $216.70 | 39.1% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $106.81 | 19.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.44 | 12.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $54.68 | 9.9% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $44.72 | 8.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.36 | 6.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $26.93 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $553.64 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $106.95 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $106.81 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $85.17 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.39 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $44.72 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.84 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.04 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $26.93 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 80 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
115 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 982 | 283 |
| Omeprazole | Omeprazole | 539 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 525 | 140 |
| Lisinopril | Lisinopril | 463 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 416 | 112 |
| Gabapentin | Gabapentin | 402 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 331 | 85 |
| Losartan Potassium | Losartan Potassium | 292 | 83 |
| Simvastatin | Simvastatin | 280 | 75 |
| Trazodone Hcl | Trazodone Hcl | 270 | 65 |
| Metformin Hcl | Metformin Hcl | 264 | 80 |
| Metformin Hcl Er | Metformin Hcl | 246 | 67 |
| Sertraline Hcl | Sertraline Hcl | 235 | 60 |
| Furosemide | Furosemide | 225 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 222 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 203 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 56 |
| Citalopram Hbr | Citalopram Hydrobromide | 174 | 42 |
| Montelukast Sodium | Montelukast Sodium | 168 | 49 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 166 | 133 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 51 |
| Valsartan | Valsartan | 157 | 52 |
| Allopurinol | Allopurinol | 154 | 42 |
| Atenolol | Atenolol | 151 | 38 |
| Eliquis | Apixaban | 135 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 134 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 125 | 28 |
| Potassium Chloride | Potassium Chloride | 118 | 42 |
| Trulicity | Dulaglutide | 115 | 15 |
| Glimepiride | Glimepiride | 113 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 113 | 25 |
| Prednisone | Prednisone | 110 | 77 |
| Meloxicam | Meloxicam | 107 | 29 |
| Xarelto | Rivaroxaban | 101 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 21 |
| Azithromycin | Azithromycin | 92 | 80 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 26 |
| Ezetimibe | Ezetimibe | 85 | 20 |
| Glipizide | Glipizide | 82 | 26 |
| Nortriptyline Hcl | Nortriptyline Hcl | 82 | 27 |
| Januvia | Sitagliptin Phosphate | 81 | 20 |
| Alprazolam | Alprazolam | 80 | 22 |
| Jardiance | Empagliflozin | 80 | 18 |
| Buspirone Hcl | Buspirone Hcl | 79 | 16 |
| Ozempic | Semaglutide | 78 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 72 | 41 |
| Doxazosin Mesylate | Doxazosin Mesylate | 67 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 13 |
| Spironolactone | Spironolactone | 65 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 19 |
| Lorazepam | Lorazepam | 59 | 24 |
| Methocarbamol | Methocarbamol | 59 | 14 |
| Carvedilol | Carvedilol | 57 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 16 |
| Baclofen | Baclofen | 55 | 18 |
| Farxiga | Dapagliflozin Propanediol | 55 | 13 |
| Synthroid | Levothyroxine Sodium | 54 | 14 |
| Promethazine Hcl | Promethazine Hcl | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Celecoxib | Celecoxib | 50 | 16 |
| Meclizine Hcl | Meclizine Hcl | 50 | 21 |
| Gemfibrozil | Gemfibrozil | 48 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 47 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 37 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | suppressed |
| Acyclovir | Acyclovir | 43 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 11 |
| Finasteride | Finasteride | 42 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Famotidine | Famotidine | 40 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 32 |
| Folic Acid | Folic Acid | 39 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Tradjenta | Linagliptin | 35 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 32 | 25 |
| Diazepam | Diazepam | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 20 |
| Irbesartan | Irbesartan | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 15 |
| Naproxen | Naproxen | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 21 | suppressed |
| Clotrimazole | Clotrimazole | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | 11 |
| Olanzapine | Olanzapine | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Topiramate | Topiramate | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $553.64 · 28 records | Novo Nordisk Inc | AIRSUPRA, Dexcom G6 Transmitter, FARXIGA, JARDIANCE, Korlym, MOUNJARO, Ozempic, QULIPTA, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error